echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > FDA approved new drug inventory in the first half of 2014: breakthrough in quantity and decrease in gold content

    FDA approved new drug inventory in the first half of 2014: breakthrough in quantity and decrease in gold content

    • Last Update: 2014-08-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Xinkangjie 2014-08-26 there is no doubt that 2014 is a colorful year for FDA to approve new drugs, and 50 new drugs will be approved It is expected that the sales volume in the United States will reach 17.2 billion dollars in 2019, and the number of new drugs approved may break the record of the past years There is no doubt that 2014 will be a year with strong color for FDA approval of new drugs, and 50 new drugs will be approved It is expected that the sales volume in the United States will reach 17.2 billion US dollars in 2019, and the number of new drugs approved may break the record of previous years, but the sales volume in 2019 fails to break the record of new drugs approved in 2013 Sovaldi approved in 2013 It is expected to create a historical record of new drugs on the market over the years, so that the total expected sales volume of new drugs approved in 2013 will become an insurmountable peak after five years (Figure 1) Figure 1 data source of FDA new drug approval volume and expected sales volume in the United States five years after its launch: 27 products of evaluatepharma have been approved in the first half of the year, and the annual sales volume in the United States is expected to reach 7 billion US dollars five years later Although the number of approved drugs in the same period has set a historical record, the gold content of approved new drugs has declined slightly So far, only one new drug is expected to become a blockbuster: otezla, an anti rheumatic drug of celgene Corporation, with an expected sales volume of barely $1.1 billion in 2019 In addition, the anti-cancer drugs cyramza, AstraZeneca, farxiga and GSK for chronic obstructive pulmonary disease (COPD) were approved Zydelig, Gilead's first entry into the anti-tumor drug market, was approved in July The expected sales of the drug in the United States in 2019 may exceed $500 million (Table 1) Table 1 Top 5 data source of gold content of new drugs approved by FDA as of the end of July 2014: hepatitis C and tumor immunity field of evaluatepharma will become the leading role of new drug approval by FDA in the second half of the year In the field of hepatitis C treatment, the combination of sowaldi and ledipasvir with Gilead will be eligible for breakthrough treatment, in addition to three molecular mixtures of abbvie; the heavyweight biopharmaceutical pembrolizumab of Merck & Co in the field of tumor immunity will be approved, and the U.S expected sales of the drug in 2019 will be nearly $20 (Table 2) Table 2 Overview data sources of new drugs to be approved in the second half of 2014: evaluatepharma, the three drugs mentioned above will be the top 3 of the drugs to be approved in the second half of the year in 2019 in the United States In addition, among the 24 new drugs to be approved in the second half of the year, anti-tumor and hepatitis C drugs account for 5 Seats, these drugs will ensure a stable return on investment in the field of anti-tumor and hepatitis C treatment.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.